Phio Pharmaceuticals regains compliance with Nasdaq listing rules

Phio Pharmaceuticals announced that it has received a letter from The Nasdaq Stock Market advising the Company that it has regained compliance with Nasdaq’s minimum bid price listing requirement. Phio has satisfied the terms of the Nasdaq Listing Qualifications Panel by complying with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550, and all other criteria for continued listing. Accordingly, Nasdaq has advised that the matter is now closed.